Trials / Completed
CompletedNCT00788944
Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl
An Open-Label Study To Evaluate The Prevalence Of Phenotypic Poor Metabolizers At CYP2D6 Among Venlafaxine-Treated Outpatients With Depression
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 971 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to determine the percentage of patients with depression who are treated with extended-release venlafaxine HCl (U.S. marketed brand Effexor XR®) who are Poor Metabolizers (based on the levels of the drug in the blood) at 2D6 (a system in the liver that breaks down some medications and other chemicals).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | blood draw | Test Article was not provided to subjects for this study. |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2008-11-11
- Last updated
- 2011-01-07
Locations
52 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00788944. Inclusion in this directory is not an endorsement.